Tetsuji Kamata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tetsuji Kamata has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Y Ikeda
5 shared publicationsK Watanabe
4 shared publications- Makoto Handa
Departments of Transfusion Medicine & Cell Therapy, School of Medicine, Keio University, Tokyo, Japan
4 shared publications Y Araki
4 shared publicationsY Kawai
4 shared publications- Yoshikazu Takada
Department of Dermatology, University of California School of Medicine, Research III Suite 3300, 4645 Second Ave., Sacramento, CA 95817, USA
4 shared publications
Latest Publications
- Open Access
- 1 December 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (49) , 38428-38437
Structural Requirements for Activation in αIIbβ3 Integrin
- 1 December 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (49) , 38428-38437
Open AccessStructural Requirements for Activation in αIIbβ3 Integrin
- Open Access
- 1 July 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (26) , 24775-24783
Membrane-proximal α/β Stalk Interactions Differentially Regulate Integrin Activation
- 1 July 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (26) , 24775-24783
Open AccessMembrane-proximal α/β Stalk Interactions Differentially Regulate Integrin Activation
- 1 March 2002
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 168 (5) , 2296-2301
The Role of the CPNKEKEC Sequence in the β2 Subunit I Domain in Regulation of Integrin αLβ2 (LFA-1)
The αL I (inserted or interactive) domain of integrin αLβ2 undergoes conformational changes upon activation. Recent studies show that the isolated, activated αL I domain is sufficient for strong ligand binding, suggesting the β2 subunit to be only indirectly involved. It has been unclear whether the activity of the αL I domain is regulated by the β2 subunit. In this study, we demonstrate that swapping the disulfide-linked CPNKEKEC sequence (residues 169–176) in the β2 I domain with a corresponding β3 sequence, or mutating Lys174 to Thr, constitutively activates αLβ2 binding to ICAM-1. These mutants do not require Mn2+ for ICAM-1 binding and are insensitive to the inhibitory effect of Ca2+. We have also localized a component of the mAb 24 epitope (a reporter of β2 integrin activation) in the CPNKEKEC sequence. Glu173 and Glu175 of the β2 I domain are identified as critical for mAb 24 binding. Because the epitope is highly expressed upon β2 integrin activation, it is likely that the CPNKEKEC sequence is exposed or undergoes conformational changes upon activation. Deletion of the αL I domain did not eliminate the mAb 24 epitope. This confirms that the αL I domain is not critical for mAb 24 binding, and indicates that mAb 24 detects a change expressed in part in the β2 subunit I domain. These results suggest that the CPNKEKEC sequence of the β2 I domain is involved in regulating the αL I domain.
- 1 March 2002
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 168 (5) , 2296-2301
The Role of the CPNKEKEC Sequence in the β2 Subunit I Domain in Regulation of Integrin αLβ2 (LFA-1)
The αL I (inserted or interactive) domain of integrin αLβ2 undergoes conformational changes upon activation. Recent studies show that the isolated, activated αL I domain is sufficient for strong ligand binding, suggesting the β2 subunit to be only indirectly involved. It has been unclear whether the activity of the αL I domain is regulated by the β2 subunit. In this study, we demonstrate that swapping the disulfide-linked CPNKEKEC sequence (residues 169–176) in the β2 I domain with a corresponding β3 sequence, or mutating Lys174 to Thr, constitutively activates αLβ2 binding to ICAM-1. These mutants do not require Mn2+ for ICAM-1 binding and are insensitive to the inhibitory effect of Ca2+. We have also localized a component of the mAb 24 epitope (a reporter of β2 integrin activation) in the CPNKEKEC sequence. Glu173 and Glu175 of the β2 I domain are identified as critical for mAb 24 binding. Because the epitope is highly expressed upon β2 integrin activation, it is likely that the CPNKEKEC sequence is exposed or undergoes conformational changes upon activation. Deletion of the αL I domain did not eliminate the mAb 24 epitope. This confirms that the αL I domain is not critical for mAb 24 binding, and indicates that mAb 24 detects a change expressed in part in the β2 subunit I domain. These results suggest that the CPNKEKEC sequence of the β2 I domain is involved in regulating the αL I domain.
- 16 November 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 74 (4) , 382-389
Platelet Integrin αIIbβ3-Ligand Interactions: What Can We Learn From the Structure?
- 16 November 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 74 (4) , 382-389
Platelet Integrin αIIbβ3-Ligand Interactions: What Can We Learn From the Structure?
- Open Access
- 1 November 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (47) , 44275-44283
Amino Acid Residues in the αIIb Subunit That Are Critical for Ligand Binding to Integrin αIIbβ3 Are Clustered in the β-Propeller Model
- 1 November 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (47) , 44275-44283
Open AccessAmino Acid Residues in the αIIb Subunit That Are Critical for Ligand Binding to Integrin αIIbβ3 Are Clustered in the β-Propeller Model
- 1 June 1999
- Vol. 40 (6) , 494-8
[Natural killer-like T-cell lymphoma appearing in the duodenum with recurrence in a variety of extranodal organs].
A 48-year-old man was admitted to Keio University Hospital in April 1995 with complaints of right abdominal pain and weight loss. Hypotonic duodenography showed a mass located in the 3rd portion of the duodenum. Endoscopic biopsy specimens disclosed diffuse large cell non-Hodgkin's lymphoma of the duodenum. The patient was initially treated with 2 courses of CHOP, albeit with no response. A pancreatoduodenectomy and radiotherapy yielded a complete remission. A year later, lymphoma recurred in the right mandible salivary gland, and a second complete remission was obtained after 6 courses of CHOP and radiation. However lymphomas also recurred in the intestine, and lungs, and the patient died of disease progression 38 months after diagnosis. Lymphoma cells were surface CD3 and CD56 positive. An examination of resected intestinal tissues disclosed lymphoma cells morphologically resemble large granular lymphocytes with rearranged TcR genes. These findings indicated the diagnosis of natural killer-like (NK-like) T-cell lymphoma. Compared with previously reported cases of NK-like T-cell lymphoma, this case was noteworthy for an unusual clinical course characterized by initial appearance in the duodenum, recurrence in a variety of extranodal organs, and the relatively long-term survival of the patient.
- 1 June 1999
- Vol. 40 (6) , 494-8
[Natural killer-like T-cell lymphoma appearing in the duodenum with recurrence in a variety of extranodal organs].
A 48-year-old man was admitted to Keio University Hospital in April 1995 with complaints of right abdominal pain and weight loss. Hypotonic duodenography showed a mass located in the 3rd portion of the duodenum. Endoscopic biopsy specimens disclosed diffuse large cell non-Hodgkin's lymphoma of the duodenum. The patient was initially treated with 2 courses of CHOP, albeit with no response. A pancreatoduodenectomy and radiotherapy yielded a complete remission. A year later, lymphoma recurred in the right mandible salivary gland, and a second complete remission was obtained after 6 courses of CHOP and radiation. However lymphomas also recurred in the intestine, and lungs, and the patient died of disease progression 38 months after diagnosis. Lymphoma cells were surface CD3 and CD56 positive. An examination of resected intestinal tissues disclosed lymphoma cells morphologically resemble large granular lymphocytes with rearranged TcR genes. These findings indicated the diagnosis of natural killer-like (NK-like) T-cell lymphoma. Compared with previously reported cases of NK-like T-cell lymphoma, this case was noteworthy for an unusual clinical course characterized by initial appearance in the duodenum, recurrence in a variety of extranodal organs, and the relatively long-term survival of the patient.
- 1 July 1997
- Vol. 42, 1679-86
[Molecular mechanisms of integrin-ligand interaction].
- 1 September 1996
- p. 16-23
[Integrin family].
- 1 March 1992
- p. 15-25
[Function of GMP-140, a granule membrane protein of platelets].
- 1 October 1990
- p. 60-5
Enhancing effect by heparin on shear-induced platelet aggregation.
We have recently developed a new device for continuously measuring SIPA. Using the device, we have investigated the effects of heparin on SIPA. Heparin itself enhanced SIPA in the absence of agonists in a dose-dependent manner, whereas heparinoids had minimal effects on SIPA. LMW heparin had less enhancing effect on SIPA than unfractionated heparin. Effects of heparin were also investigated using PRP from patients with congenital bleeding disorders, including Bernard-Soulier syndrome, type III von Willebrand's disease, afibrinogenemia and Glanzmann's thrombasthenia. Heparin's effects were observed only when PRP from patients with Bernard-Soulier syndrome and type III von Willebrand's disease was exposed to low shear stress and when PRP from a patient with afibrinogenemia was exposed to high shear stress. These results gave us insights into heparin's effects on platelet aggregation.
- 1 October 1990
- p. 60-5
Enhancing effect by heparin on shear-induced platelet aggregation.
We have recently developed a new device for continuously measuring SIPA. Using the device, we have investigated the effects of heparin on SIPA. Heparin itself enhanced SIPA in the absence of agonists in a dose-dependent manner, whereas heparinoids had minimal effects on SIPA. LMW heparin had less enhancing effect on SIPA than unfractionated heparin. Effects of heparin were also investigated using PRP from patients with congenital bleeding disorders, including Bernard-Soulier syndrome, type III von Willebrand's disease, afibrinogenemia and Glanzmann's thrombasthenia. Heparin's effects were observed only when PRP from patients with Bernard-Soulier syndrome and type III von Willebrand's disease was exposed to low shear stress and when PRP from a patient with afibrinogenemia was exposed to high shear stress. These results gave us insights into heparin's effects on platelet aggregation.